acamprosate vs valbenazine
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of acamprosate and valbenazine. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Campral
Ingrezza
Acamprosate is a medicine that can help you stay away from alcohol if you are alcohol-dependent and have already stopped drinking. It should be used with counseling and support.
Ingrezza and Ingrezza Sprinkle are medicines used to treat movement problems. They can help with tardive dyskinesia and chorea caused by Huntington's disease.
Acamprosate helps people who are alcohol-dependent to not drink alcohol. You must have already stopped drinking before you start taking acamprosate. This medicine works best when it is part of a complete treatment plan that includes counseling and support.
This medicine treats tardive dyskinesia in adults. Tardive dyskinesia causes repetitive, uncontrolled movements. It also treats chorea, which is involuntary, jerky movements, in adults with Huntington's disease.
Acamprosate is similar to a natural substance in your brain. It is thought to work by helping to restore the normal balance of brain activity that is changed by long-term alcohol use. This can reduce your craving for alcohol.
Ingrezza works by affecting a protein in your brain called VMAT2. This protein helps control the release of certain chemicals. By blocking VMAT2, Ingrezza helps reduce unwanted movements.
- • Accidental injury
- • Weakness
- • Pain
- • Loss of appetite
- • Diarrhea
- • Sleepiness
- • Lethargy
- • Sedation
- • Urticaria (hives)
- • Rash
- Hypotension 14
- Asthenia 13
- Condition Aggravated 13
- Acute Kidney Injury 12
- Coma 12
- Somnolence 2,412
- Fatigue 1,646
- Tremor 1,539
- Tardive Dyskinesia 1,471
- Fall 1,104
Acamprosate may increase the risk of suicidal thoughts or actions. Your doctor should watch you for depression or suicidal thoughts. Tell your doctor right away if you have any new or worsening symptoms of depression or suicidal thoughts.
Ingrezza can increase the risk of depression and suicidal thoughts in people with Huntington's disease. Your doctor will monitor you closely for any changes in mood or behavior. Tell your doctor right away if you have any thoughts of harming yourself.
Acamprosate may harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if acamprosate passes into breast milk. Talk to your doctor if you are breastfeeding.
Ingrezza may harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. You should not breastfeed while taking Ingrezza.
Also Compare, Nearby Drugs
Compare valbenazine with
How to Read This acamprosate vs valbenazine Comparison
acamprosate is classified in the GABA Analog (Alcohol Dependence) drug class, while valbenazine sits within the VMAT2 Inhibitor class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, acamprosate has 64 submissions while valbenazine has 8,172. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for acamprosate or valbenazine.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.